Medicare coverage unlocked, FDA clearance pending — GraftAssure's commercial future depends on authorization before cash runs out

Insight Molecular Diagnostics is a commercial-stage molecular diagnostics company developing GraftAssure, a blood test to detect kidney transplant rejection, which is not yet FDA-approved.

GraftAssure, a dd-cfDNA blood test that monitors kidney transplant rejection, secured favorable Medicare coverage decisions in July 2026, including expanded surveillance reimbursement, with Lancet-published data showing its utility in guiding anti-rejection therapy. FDA clearance of GraftAssureDx is the binary that determines whether the thesis holds, but cash of roughly $19M against a $10M quarterly burn leaves fewer than two quarters of runway. The central risk is that FDA requests further delay the authorization past the point the company can fund operations without additional dilutive financing.